Loading...
XNYS
BAX
Market cap14bUSD
Jul 14, Last price  
28.53USD
1D
-0.59%
1Q
2.63%
Jan 2017
-35.66%
Name

Baxter International Inc

Chart & Performance

D1W1MN
No data to show
P/E
—
P/S
3.24
EPS
—
Div Yield, %
3.05%
Shrs. gr., 5y
-0.35%
Rev. gr., 5y
-16.86%
Revenues
4.51b
-69.53%
9,849,000,00010,378,000,00011,263,000,00012,348,000,00012,562,000,00012,843,000,00013,893,000,00014,190,000,00015,259,000,00016,671,000,0009,968,000,00010,163,000,00010,561,000,00011,127,000,00011,362,000,00011,673,000,00012,784,000,00015,113,000,00014,813,000,0004,513,000,000
Net income
-312m
L
956,000,0001,396,000,0001,707,000,0002,014,000,0002,205,000,0001,420,000,0002,224,000,0002,326,000,0002,012,000,0002,497,000,000968,000,0004,965,000,000717,000,0001,624,000,0001,001,000,0001,102,000,0001,284,000,000-2,421,000,0002,656,000,000-312,000,000
CFO
1.02b
-40.96%
1,550,000,0002,183,000,0002,305,000,0002,515,000,0002,909,000,0003,003,000,0002,817,000,0003,106,000,0003,198,000,0003,215,000,0001,647,000,0001,624,000,0001,837,000,0002,096,000,0002,104,000,0001,868,000,0002,222,000,0001,211,000,0001,726,000,0001,019,000,000
Dividend
Aug 30, 20240.29 USD/sh
Earnings
Aug 04, 2025

Profile

Baxter International Inc., through its subsidiaries, develops and provides a portfolio of healthcare products worldwide. The company offers peritoneal dialysis and hemodialysis, and additional dialysis therapies and services; intravenous therapies, infusion pumps, administration sets, and drug reconstitution devices; remixed and oncology drug platforms, inhaled anesthesia and critical care products and pharmacy compounding services; parenteral nutrition therapies and related products; biological products and medical devices used in surgical procedures for hemostasis, tissue sealing and adhesion prevention; and continuous renal replacement therapies and other organ support therapies focused in the intensive care unit. It also provides connected care solutions, including devices, software, communications, and integration technologies; integrated patient monitoring and diagnostic technologies to help diagnose, treat, and manage a various illness and diseases, including respiratory therapy, cardiology, vision screening, and physical assessment; surgical video technologies, tables, lights, pendants, precision positioning devices and other accessories. In addition, the company offers contracted services to various pharmaceutical and biopharmaceutical companies. Its products are used in hospitals, kidney dialysis centers, nursing homes, rehabilitation centers, doctors' offices, and patients at home under physician supervision. The company sells its products through direct sales force, as well as through independent distributors, drug wholesalers, and specialty pharmacy or other alternate site providers in approximately 100 countries. It has an agreement with Celerity Pharmaceutical, LLC to develop acute care generic injectable premix and oncolytic molecules. Baxter International Inc. was incorporated in 1931 and is headquartered in Deerfield, Illinois.
URL
https://www.baxter.com/
IPO date
May 15, 1961
Employees
60,000
Domiciled in
US
Incorporated in
US

Valuation

Title
USD in thousands, except ratios and share amounts
FYFYFYFYFYFYFYFYFYFY
2024‑122023‑122022‑122021‑122020‑122019‑122018‑122017‑122016‑122015‑12
Income
Revenues
4,513,000
-69.53%
14,813,000
-1.99%
15,113,000
18.22%
Cost of revenue
4,196,000
14,443,000
14,208,000
Unusual Expense (Income)
NOPBT
317,000
370,000
905,000
NOPBT Margin
7.02%
2.50%
5.99%
Operating Taxes
177,000
(34,000)
68,000
Tax Rate
55.84%
7.51%
NOPAT
140,000
404,000
837,000
Net income
(312,000)
-111.75%
2,656,000
-209.71%
(2,421,000)
-288.55%
Dividends
(590,000)
(586,000)
(573,000)
Dividend yield
3.97%
3.00%
2.23%
Proceeds from repurchase of equity
95,000
BB yield
-0.37%
Debt
Debt current
2,752,000
2,796,000
1,525,000
Long-term debt
10,860,000
12,134,000
16,265,000
Deferred revenue
46,000
80,000
Other long-term liabilities
1,630,000
1,244,000
1,181,000
Net debt
11,848,000
11,542,000
15,825,000
Cash flow
Cash from operating activities
1,019,000
1,726,000
1,211,000
CAPEX
(446,000)
(692,000)
(679,000)
Cash from investing activities
(410,000)
3,213,000
(931,000)
Cash from financing activities
(1,081,000)
(3,489,000)
(1,438,000)
FCF
1,341,000
658,000
426,000
Balance
Cash
1,764,000
3,194,000
1,718,000
Long term investments
194,000
247,000
Excess cash
1,538,350
2,647,350
1,209,350
Stockholders' equity
11,662,000
13,309,000
10,962,000
Invested Capital
20,484,650
21,474,650
22,905,650
ROIC
0.67%
1.82%
3.41%
ROCE
1.44%
1.51%
3.65%
EV
Common stock shares outstanding
510,000
506,000
504,000
Price
29.16
-24.57%
38.66
-24.15%
50.97
-40.62%
Market cap
14,871,600
-23.98%
19,561,960
-23.85%
25,688,880
-41.09%
EV
26,779,600
31,169,960
41,575,880
EBITDA
1,314,000
1,633,000
2,308,000
EV/EBITDA
20.38
19.09
18.01
Interest
408,000
512,000
395,000
Interest/NOPBT
128.71%
138.38%
43.65%